Biolyzr Aps

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 11.3% 12.6% 5.6%  
Credit score (0-100)  0 0 21 17 41  
Credit rating  N/A N/A BB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 14.8 2,133 2,993  
EBITDA  0.0 0.0 8.1 960 1,686  
EBIT  0.0 0.0 8.1 960 1,686  
Pre-tax profit (PTP)  0.0 0.0 7.8 935.0 2,303.5  
Net earnings  0.0 0.0 5.6 729.3 1,796.0  
Pre-tax profit without non-rec. items  0.0 0.0 7.8 935 2,303  

 
See the entire income statement

Balance sheet (kDKK) 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 45.6 775 2,404  
Interest-bearing liabilities  0.0 0.0 37.4 37.6 37.6  
Balance sheet total (assets)  0.0 0.0 95.8 1,286 3,426  

Net Debt  0.0 0.0 -34.2 -240 -100  
 
See the entire balance sheet

Volume 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 14.8 2,133 2,993  
Gross profit growth  0.0% 0.0% 0.0% 14,324.0% 40.3%  
Employees  0 0 0 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 96 1,286 3,426  
Balance sheet change%  0.0% 0.0% 0.0% 1,241.7% 166.4%  
Added value  0.0 0.0 8.1 959.7 1,686.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 54.7% 45.0% 56.3%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 8.4% 140.6% 98.1%  
ROI %  0.0% 0.0% 9.7% 216.9% 142.1%  
ROE %  0.0% 0.0% 12.2% 177.8% 113.0%  

Solidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  0.0% 0.0% 47.5% 60.3% 70.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -422.8% -25.0% -5.9%  
Gearing %  0.0% 0.0% 82.1% 4.8% 1.6%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1.7% 96.0% 22.1%  

Liquidity 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.0 0.0 1.9 1.3 0.7  
Current Ratio  0.0 0.0 1.9 1.3 0.7  
Cash and cash equivalent  0.0 0.0 71.6 277.3 137.6  

Capital use efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 45.6 157.2 -281.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 480 843  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 480 843  
EBIT / employee  0 0 0 480 843  
Net earnings / employee  0 0 0 365 898